Genmab A-S
Closed
1,890 1.37
Overview
Share price change
24h
Min
1851
Max
1906
Income | 21M 52M |
|---|---|
Sales | -184M 881M |
P/E Sector Avg | 21.697 60.549 |
EPS | 8.48 |
Profit margin | 5.915 |
Employees | 3,088 |
EBITDA | -30M 215M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | -1.49% downside |
Next Earnings | 6 Aug 2026 |
|---|
Market Cap | 10B 115B |
|---|---|
Previous open | 1888.63 |
Previous close | 1890 |
Genmab A-S Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Genmab A-S Forecast
Price Target
By TipRanks
-1.49% downside
12 Months Forecast
Average 2,493.35 DKK -1.49%
High 3,320 DKK
Low 308.417 DKK
Based on 7 Wall Street analysts offering 12 month price targets forGenmab A-S - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Genmab A-S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
